Literature DB >> 1929685

Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group.

M Kleerekoper1, R S Brienza, L R Schultz, C C Johnson.   

Abstract

This cross-sectional retrospective epidemiologic study investigated risk factors for low bone mineral density (BMD) in a group of 2297 women, 76% of whom were postmenopausal. Reproductive information, history of oral contraceptive use, BMD measurements, and other data were available from women presenting to 12 osteoporosis screening centers in 1986 and 1987. Each woman was classified into a BMD category based on the range of BMD measurements at her respective center. Menopause, increasing age and years since menopause, and decreasing body mass index were associated with low BMD. A history of oral contraceptive use was protective against low BMD (odds ratio = 0.35, 95% confidence interval = 0.23 to 0.53). Multivariate analyses confirmed this result and further demonstrated that increasing duration of use was protective. These data suggest that prior use of oral contraceptive agents is associated with higher levels of BMD and that the degree of protection from lower BMD is related to duration of exposure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929685

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  15 in total

Review 1.  Effects of hormonal contraceptives on bone mineral density.

Authors:  B A Cromer
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

Review 2.  Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review.

Authors:  S L Liu; C M Lebrun
Journal:  Br J Sports Med       Date:  2006-01       Impact factor: 13.800

3.  Relative importance of body composition, osteoporosis-related behaviors, and parental income on bone speed of sound in adolescent females.

Authors:  B L Holmes; I A Ludwa; K L Gammage; D E Mack; P Klentrou
Journal:  Osteoporos Int       Date:  2010-01-22       Impact factor: 4.507

4.  Glucocorticoid-induced osteoporosis: treatment update and review.

Authors:  Lisa-Ann Fraser; Jonathan D Adachi
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

5.  Oral contraceptive treatment inhibits the normal acquisition of bone mineral in skeletally immature young adult female monkeys.

Authors:  T C Register; M J Jayo; C P Jerome
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

6.  Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women. European Vertebral Osteoporosis Study Group.

Authors:  T W O'Neill; A J Silman; M Naves Diaz; C Cooper; J Kanis; D Felsenberg
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

7.  The effect of oral contraceptive different patterns of use on circulating IGF-1 and bone mineral density in healthy premenopausal women.

Authors:  Amany Y Elkazaz; Khaled Salama
Journal:  Endocrine       Date:  2014-05-27       Impact factor: 3.633

8.  The effect of previous oral contraceptive use on bone mineral density in perimenopausal women.

Authors:  M Tuppurainen; H Kröger; S Saarikoski; R Honkanen; E Alhava
Journal:  Osteoporos Int       Date:  1994-03       Impact factor: 4.507

9.  Oral contraceptive use in young women is associated with lower bone mineral density than that of controls.

Authors:  Hawley Almstedt Shoepe; Christine M Snow
Journal:  Osteoporos Int       Date:  2005-05-19       Impact factor: 4.507

10.  The effect of past use of oral contraceptive on bone mineral density, bone biochemical markers and muscle strength in healthy pre and post menopausal women.

Authors:  Fadoua Allali; Laila El Mansouri; Fatima zohra Abourazzak; Linda Ichchou; Hamza Khazzani; Loubna Bennani; Redouane Abouqal; Najia Hajjaj-Hassouni
Journal:  BMC Womens Health       Date:  2009-11-03       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.